These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 35422812)

  • 1. Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Yang G; Xing L; Sun X
    Front Immunol; 2022; 13():852811. PubMed ID: 35422812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases.
    Yan X; Qu F; Zhou Y
    Lung Cancer; 2023 Oct; 184():107322. PubMed ID: 37611495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents.
    Yang D; Munai E; Zeng S; Tao D; Yuan Z; Du L; Zhou W; Wu Y; Zhu XD
    Cancer Immunol Immunother; 2024 Sep; 73(11):226. PubMed ID: 39237636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in NSCLC Patients with Brain Metastases.
    Buriolla S; Pelizzari G; Corvaja C; Alberti M; Targato G; Bortolot M; Torresan S; Cortiula F; Fasola G; Follador A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
    Li W; Yu H
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang Y; Deng L; Yang Y; Zhang T; Wu Y; Wang L; Bi N
    Clin Lung Cancer; 2022 Mar; 23(2):95-107. PubMed ID: 34284948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Chen H; Feng Y; Zhou Y; Tao Y; Tang L; Shi Y
    Cancer Immunol Immunother; 2022 Dec; 71(12):3071-3085. PubMed ID: 35648238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rationale and toxicity of combined cranial radiotherapy and immune checkpoint inhibitors in non-small cell lung cancer.
    Chen Y; Zhuang H; Wang J
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):165-170. PubMed ID: 32129944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.
    Wei Y; Xu Y; Wang M
    Chin Med J (Engl); 2023 Jul; 136(13):1523-1531. PubMed ID: 37106555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
    Wu X; Stabile LP; Burns TF
    Clin Lung Cancer; 2024 Sep; 25(6):483-501. PubMed ID: 38991863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
    Gridelli C; Peters S; Mok T; Forde PM; Reck M; Attili I; de Marinis F
    ESMO Open; 2022 Feb; 7(1):100355. PubMed ID: 34922299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.